Type 2 Diabetes | Pharmacor | Brazil | 2014

In 2013, Brazil’s total pharmaceutical market for type 2 diabetes rivaled the size of some of the major markets. Increasing public awareness, an aging population, and the launch of new premium-priced antidiabetic agents will all contribute to the growth of this market in the next five years. The large, growing prevalent population promises a 7% annual growth in sales and significant opportunity for multinational pharmaceutical companies as demand for branded antidiabetic drugs continues to grow throughout Brazil.